Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Fineline Cube Dec 14, 2025
Company Deals

InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program

Fineline Cube Dec 14, 2025
Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Fineline Cube Dec 13, 2025
Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Fineline Cube Dec 13, 2025
Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Fineline Cube Dec 13, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Fineline Cube Dec 14, 2025
Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Fineline Cube Dec 14, 2025
Company Drug

Zhejiang Huahai Receives FDA ANDA Approval for Generic Tecfidera

Fineline Cube Oct 28, 2022

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...

Company Deals

Novartis Expands Strategic Collaboration with Bo’Ao Lecheng Pilot Zone

Fineline Cube Oct 28, 2022

Novartis (NYSE: NVS) announced a further strategic collaboration with the Bo’Ao Lecheng Medical Tourism Pilot...

Company Deals

Salubris Partners with Alpha Molecular for AI-Driven Obesity Drug Development

Fineline Cube Oct 28, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with compatriot...

Company

RemeGen Reports 397.47% YOY Revenue Growth in Q3 2022

Fineline Cube Oct 28, 2022

China-based pharma firm RemeGen (HKG: 9995) released its Q3 2022 financial report, showing significant growth...

Company Drug

Innovent’s Parsaclisib Filed for Marketing Approval in China

Fineline Cube Oct 28, 2022

China’s Center for Drug Evaluation (CDE) has received a marketing approval application for Innovent Biologics...

Company Drug

Proheal Pharmaceuticals Initiates Clinical Study for PHP1003 in Thyroid-Associated Ophthalmopathy

Fineline Cube Oct 28, 2022

Proheal Pharmaceuticals, a Suzhou-based developer of drugs for ophthalmology and autoimmune diseases, announced the first...

Company Drug

HutchMed Initiates Phase II/III Study for Elunate and Tyvyt in Renal Cell Carcinoma

Fineline Cube Oct 28, 2022

China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase...

Company

Shanghai Pharmaceuticals Reports 12.86% YOY Revenue Growth in Q3 2022

Fineline Cube Oct 28, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) released its Q3 2022 financial report, recording RMB 62.904...

Company Drug

Recbio’s Neoadjuvant HPV Vaccine Accepted for Review by NMPA

Fineline Cube Oct 28, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced that a clinical trial...

Company Drug

Kintor Completes Enrollment for GT20029 Phase I Study in US

Fineline Cube Oct 28, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of enrollment for a Phase I...

Company Drug

Alphamab Oncology Gains NMPA Approval for JSKN003 Clinical Trial

Fineline Cube Oct 28, 2022

Alphamab Oncology (HKG: 9966) announced that it has received approval from the National Medical Products...

Company Drug

WinHealth’s Ravicti Receives Orphan Drug Designation in Taiwan

Fineline Cube Oct 28, 2022

China-based Hong Kong WinHealth Pharma Group Ltd announced that its Swiss partner Immedica Pharma AB’s...

Company Drug

Lee’s Pharmaceutical’s NVK-002 Shows Strong Results in Phase III CHAMP Study

Fineline Cube Oct 28, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced that...

Company Drug

CSPC’s Antibody-Drug Conjugate SYS6002 Gains CDE Approval for Clinical Study

Fineline Cube Oct 28, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company

Luye Pharma’s Long-Acting IL-4Rα Antibody BA2101 Gains CDE Approval

Fineline Cube Oct 28, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its controlling subsidiary Shandong Boan Biotechnology Co.,...

Company Drug

Ausper Biopharma’s COVID-19 Nasal Spray Antibody Gets NMPA Approval

Fineline Cube Oct 28, 2022

Ausper Biopharma Inc., a Hangzhou-based developer of hepatitis B virus (HBV) drugs, announced that its...

Company

Merck’s Q3 Sales Rise on Key Drug Performances, China Growth

Fineline Cube Oct 28, 2022

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) reported its Q3 2022 financial results,...

Company Deals

Salubris Partners with Anlong Bio for Small Nucleic Acid Drugs in Hypertension

Fineline Cube Oct 28, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with Beijing...

Policy / Regulatory

Shanghai Launches Inhaled COVID-19 Vaccine Booster Program

Fineline Cube Oct 28, 2022

On October 25, Shanghai began accepting patient reservations for the inhalable recombinant COVID-19 vaccine (adenovirus...

Company Drug

Ocumension Initiates Second Phase III Denali Study for OT-301 in US

Fineline Cube Oct 27, 2022

China-based Ocumension Therapeutics (HKG: 1477) announced the initiation of a second Phase III Denali study...

Posts pagination

1 … 540 541 542 … 597

Recent updates

  • Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation
  • Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
  • Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
  • Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment
  • InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.